Skip to main navigation Skip to search Skip to main content

Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone

  • Ryan Reshke
  • , James A. Taylor
  • , Alexandre Savard
  • , Huishan Guo
  • , Luke H. Rhym
  • , Piotr S. Kowalski
  • , My Tran Trung
  • , Charles Campbell
  • , Wheaton Little
  • , Daniel G. Anderson
  • , Derrick Gibbings
  • University of Ottawa
  • Massachusetts Institute of Technology
  • Takeda Pharmaceutical Company Limited

Research output: Contribution to journalArticlepeer-review

Abstract

A small percentage of the short interfering RNA (siRNA) delivered via passive lipid nanoparticles and other delivery vehicles reaches the cytoplasm of cells. The high doses of siRNA and delivery vehicle that are thus required to achieve therapeutic outcomes can lead to toxicity. Here, we show that the integration of siRNA sequences into a Dicer-independent RNA stem–loop based on pre-miR-451 microRNA—which is highly enriched in small extracellular vesicles secreted by many cell types—reduces the expression of the genes targeted by the siRNA in the liver, intestine and kidney glomeruli of mice at siRNA doses that are at least tenfold lower than the siRNA doses typically delivered via lipid nanoparticles. Small extracellular vesicles that efficiently package siRNA can significantly reduce its therapeutic dose.

Original languageEnglish
Pages (from-to)52-68
Number of pages17
JournalNature Biomedical Engineering
Volume4
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone'. Together they form a unique fingerprint.

Cite this